RESUMEN
The Society for Cardiovascular Angiography and Interventions (SCAI) Think Tank is a collaborative venture that brings together interventional cardiologists, administrative partners, and select members of the cardiovascular industry community annually for high-level field-wide discussions. The 2021 Think Tank was organized into four parallel sessions reflective of the field of interventional cardiology: (a) coronary intervention, (b) endovascular medicine, (c) structural heart disease, and (d) congenital heart disease. Each session was moderated by a senior content expert and co-moderated by a member of SCAI's Emerging Leader Mentorship program. This document presents the proceedings to the wider cardiovascular community in order to enhance participation in this discussion, create additional dialog from a broader base, and thereby aid SCAI, the industry community and external stakeholders in developing specific action items to move these areas forward.
Asunto(s)
Cardiólogos , Cardiología , Cardiopatías Congénitas , Angiografía , Humanos , Resultado del TratamientoAsunto(s)
Comités Consultivos , Circulación Asistida/instrumentación , Conferencias de Consenso como Asunto , Medicina Basada en la Evidencia , Ensayos Clínicos Controlados Aleatorios como Asunto , Choque Cardiogénico , Circulación Asistida/efectos adversos , Investigación Biomédica , Instituciones Cardiológicas/clasificación , Aprobación de Recursos/legislación & jurisprudencia , Urgencias Médicas , Hemodinámica , Humanos , Consentimiento Informado/legislación & jurisprudencia , Consentimiento Informado/normas , Selección de Paciente , Probabilidad , Síntomas Prodrómicos , Estándares de Referencia , Proyectos de Investigación , Índice de Severidad de la Enfermedad , Choque Cardiogénico/diagnóstico , Choque Cardiogénico/mortalidad , Choque Cardiogénico/terapia , Sociedades Médicas , Accidente Cerebrovascular/etiología , Tiempo de Tratamiento , Resultado del Tratamiento , TriajeRESUMEN
OBJECTIVES: To determine feasibility, safety, and adoption rates of right heart catheterization (RHC) using antecubital venous access (AVA) as compared to using the traditional approach of proximal venous access (PVA). BACKGROUND: RHC via PVA (i.e., internal jugular, femoral or subclavian) is generally a low risk procedure; however, complications may occur and are usually access site related. RHC via an antecubital approach has regained attention given the increase in transradial left heart catheterizations. METHODS: Patients undergoing RHC for any indication at a single large academic medical center were identified over a 5-year period (January 2008 to December 2012) from a database. Medical records were retrospectively analyzed for demographic, procedural and outcomes data. RESULTS: Two hundred seventy-two RHC procedures were included (106 AVA, 166 PVA). The adoption rate of AVA for RHC increased rapidly since its introduction in our laboratory in 2010 (100% PVA in 2008 and 2009, 85% AVA in 2012). All procedures were successful; however, 6% of procedures required additional, alternate access to the original site. Initial success rates were similar in the two groups (91 vs. 96% for AVA and PVA respectively, P = 0.12). Fluoroscopy time was shorter in the group of patients who underwent the procedure via AVA. The complication rate was 0% in the AVA group compared with 3% in the PVA group (P = 0.16). CONCLUSION: RHC via the AVA is a feasible and safe alternative to PVA. Our experience and rapid adoption support the use AVA as the access site of choice for RHC in uncomplicated patients.
Asunto(s)
Cateterismo Cardíaco/métodos , Cateterismo Venoso Central/métodos , Cardiopatías/diagnóstico , Centros de Atención Terciaria/estadística & datos numéricos , Anciano , Estudios de Factibilidad , Femenino , Estudios de Seguimiento , Humanos , Masculino , Persona de Mediana Edad , Reproducibilidad de los Resultados , Estudios Retrospectivos , Vena SubclaviaAsunto(s)
Reestenosis Coronaria/cirugía , Estenosis Coronaria/diagnóstico , Estenosis Coronaria/terapia , Stents Liberadores de Fármacos , Sirolimus/administración & dosificación , Angina Inestable/etiología , Angina Inestable/fisiopatología , Implantación de Prótesis Vascular , Angiografía Coronaria , Puente de Arteria Coronaria , Reestenosis Coronaria/diagnóstico , Reestenosis Coronaria/etiología , Reestenosis Coronaria/patología , Estenosis Coronaria/patología , Estenosis Coronaria/fisiopatología , Vasos Coronarios/efectos de los fármacos , Vasos Coronarios/patología , Vasos Coronarios/cirugía , Humanos , Imagenología Tridimensional , Lípidos , Masculino , Persona de Mediana Edad , Tomografía de Coherencia Óptica , Insuficiencia del TratamientoRESUMEN
The prevalence of metabolic syndrome (MS) was determined in patients aged < or =45 years who presented with acute myocardial infarction and underwent primary percutaneous coronary intervention. Two hundred twenty-three consecutive patients aged 18 to 45 years who underwent cardiac catheterization for acute myocardial infarction from June 2001 to December 2004 were reviewed. MS was diagnosed by National Cholesterol Education Program Adult Treatment Panel III guidelines (modified by substituting body mass index > or =28.8 kg/m2 for waist circumference). One hundred sixty-one patients met all 5 criteria for MS available for evaluation. Seventy-six of these patients (47%) met > or =3 of the 5 criteria for MS. Sixteen patients with MS (21%) and 5 patients without MS (6%) had diabetes mellitus. The prevalence of each criterion was significantly higher (p <0.05) in the MS group. Average Framingham risk scores were 7.0 and 4.5 for patients with and without MS, respectively. The prevalence of smoking, male gender, and family history of premature coronary artery disease were the same for the 2 groups. In conclusion, MS was highly prevalent in this population of young patients with acute myocardial infarction.
Asunto(s)
Angioplastia Coronaria con Balón , Síndrome Metabólico/epidemiología , Infarto del Miocardio/terapia , Adolescente , Adulto , Factores de Edad , Femenino , Humanos , Masculino , Síndrome Metabólico/complicaciones , Persona de Mediana Edad , Infarto del Miocardio/etiología , Prevalencia , Factores Sexuales , Fumar/efectos adversos , Estados Unidos/epidemiologíaRESUMEN
BACKGROUND: Percutaneous peripheral arterial intervention (PPAI) has emerged as an effective and less invasive alternative to surgery for peripheral arterial disease (PAD), however, data on gender differences in outcome of PPAI, especially in the stent era, are limited. The purpose of this study was to assess the gender differences on in-hospital outcomes of patients undergoing PPAI. METHODS: We analyzed data on 268 consecutive patients (women: 122; men: 146) who underwent PPAI for PAD between October 2001 and January 2004. A total of 405 lesions (women: 184; men: 221) were treated. RESULTS: Background characteristics were similar except for less prevalent prior coronary intervention in women (18.0% versus 28.8%; p = 0.04), and more prevalent current smokers in women (22.1% versus 12.3%; p = 0.03). Upper extremities interventions were performed more often in women (9.2% versus 3.2%; p = 0.01). Procedure success was achieved in 89.3% of women and 89.7% of men (p = NS). In-hospital mortality was similar between women and men (1.6% versus 0.7%; p = NS). However, hemorrhagic complications occurred more frequently in women (7.4% versus 0.7%; p = 0.006). The blood transfusion rate was significantly higher in women (6.6% versus 0.7%; p = 0.013). Female gender was the only independent predictor of hemorrhagic complications (OR = 12.2; 95% CI = 1.39-111.1; p = 0.024). CONCLUSIONS: Percutaneous intervention for PAD can be performed in women with similar success rates as in men, albeit with a greater than 10-fold higher risk of hemorrhagic complications.